Approvals and designations made by the U.S. Food and Drug Administration for the week ended Aug. 30.
Approvals
* Kyowa Kirin Co. Ltd.'s Nourianz as an add-on treatment for adults with Parkinson's disease experiencing so-called off episodes — times when a patient's medications are not working well and symptoms, such as tremor and difficulty walking, increase.
* Eli Lilly and Co.'s Taltz injection for adults with active ankylosing spondylitis, also known as radiographic axial spondyloarthritis.
* Mylan NV's generic version of Eli Lilly's lung cancer drug Alimta. The FDA granted tentative approval to Mylan.
* Alcon Inc.'s AcrySof IQ PanOptix trifocal intraocular lens for patients undergoing cataract surgery.
|
Fast track
* AstraZeneca PLC's Farxiga in delaying the progression of renal failure, as well as prevent cardiovascular and renal death in chronic kidney disease patients, with or without type 2 diabetes.
Other designations: orphan drug
* AstraZeneca's Fasenra for eosinophilic esophagitis.
* Akari Therapeutics PLC's nomacopan for patients with hematopoietic stem cell transplant-associated thrombotic microangiopathy.

FDA headquarters in Silver Spring, Md.